Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: The ERECT Trial

Hiten D Patel; Mohamad E Allaf

doi:10.1016/j.euf.2018.01.002

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: The ERECT Trial

Eur Urol Focus. 2019 Jul;5(4):698-699. doi: 10.1016/j.euf.2018.01.002. Epub 2018 Jan 17.

Authors

Hiten D Patel¹, Mohamad E Allaf²

Affiliations

¹ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: hitenpatel@jhmi.edu.
² The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 29373284
DOI: 10.1016/j.euf.2018.01.002

Abstract

Erythropoietin receptors have been localized to human penile tissue and periprostatic neurovascular bundles. ERECT is a placebo-controlled, phase 2, randomized trial assessing the effect of erythropoietin on recovery of erectile function for men undergoing radical prostatectomy for prostate cancer.

Publication types

Clinical Trial Protocol

MeSH terms

Clinical Trials, Phase II as Topic
Erectile Dysfunction / drug therapy*
Erythropoietin / therapeutic use*
Humans
Male
Postoperative Complications / etiology*
Prostatectomy*
Prostatic Neoplasms / surgery*
Randomized Controlled Trials as Topic
Recovery of Function

Substances

EPO protein, human
Erythropoietin